drugset / Trial / NCT00690235
Demonstrate the Effects of Pramlintide on Weight Reduction in Schizophrenia
Phase 4
Completed
33 enrolled
University of Texas Southwestern Medical Center
Amylin Pharmaceuticals, LLC. · collab
RandomizedParallel-groupDouble-blindOther
Summary
Primary Objective: To test the effect of pramlintide on body weight in clozapine- and olanzapine-induced weight gain in persons with schizophrenia who are currently taking either drug; measures of the metabolic syndrome will be evaluated as well.
Timeline
- Start
- 2007-11
- Primary completion
- 2011-08
- Completion
- 2011-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pramlintide | Peptide | 360 ug | Subcutaneous |